Capricor Therapeutics and Nippon Shinyaku Expand Partnership for Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan
Capricor Therapeutics has announced that it has entered into a partnership with Nippon Shinyaku Co., Ltd . for the exclusive commercialization and distribution in Japan of Capricor’s lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy which is a rare neuromuscular disease.
According to the terms of the contract, Capricor will be given a $12 million upfront payment, as well as further research and sales-based milestone payments that could total up to $89 million and product revenue. According to the conditions of the U.S. contract with Nippon Shinyaku, Capricor will be in charge of clinical development while Nippon Shinyaku will be in charge of distributing CAP-1002 in Japan after it has received approval. Nippon Shinyaku will purchase commercial goods from Capricor. If the product is authorised in Japan, Capricor will also possess the country’s marketing authorization.
CAP-1002 product consists of allogeneic cardiosphere-derived cells (CDCs), a type of progenitor cell that has been shown in pre-clinical and clinical studies to exert potent immuno-modulatory activity and is being investigated for its potential to modify the immune system’s activity to encourage cellular regeneration.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases.